Company intelligence / Profile preview

Akros Pharma Inc.

Princeton, New Jersey, United Statesakrospharma.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Akros Pharma Inc. is a US-based subsidiary of JT Pharmaceuticals focused on developing innovative small molecule drugs for global markets. Its pipeline includes candidates targeting chronic heart failure, anaphylaxis, autoimmune diseases, and diabetes. Some assets have reached approval in Japan; US clinical development is ongoing with lead programs in Phase 2 trials.[6][9]

Therapeutic areas: ImmunologyCardiovascularEndocrinology
Modalities: Small molecule drugs[6][9]
Industry: Biotech

Drug pipeline

1 asset

tirbanibulin

Commercial

Indications: Actinic keratosis

Partnerships

Collaborates closely with parent company JT Pharmaceuticals and its Japanese commercial arm Torii Pharmaceutical Co., Ltd.[2].

Beyond the preview

Go deeper on Akros Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akros Pharma Inc..

Explore the full profile